ResultsIQ › Latest results › 3B Blackbio Dx Limited
3B Blackbio Dx Limited Q4 FY26 earnings call summary
NSE: 3BBLACKBIO · BSE: 532067
Earnings call of 1 Jun 2026, summarised by AI from the filing.
3B BlackBio Dx reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, guiding 15-20% growth in FY27.
Key takeaways
- FY27 guidance Management targets 15% to 20% revenue and EBITDA growth in FY27.
- Growth driver International expansion through TRUPCR Europe and Coris, plus US FDA submission for AMR products.
- Risk Chinese competition in respiratory and Entero products pressures Coris margins.
3B Blackbio Dx Limited earnings call, investor presentation and press release summaries
- Q1 FY27: Results deck (13 Aug 2026)
- Q4 FY26: Earnings call (1 Jun 2026), Results deck (29 May 2026)
- Q3 FY26: Earnings call (21 Feb 2026), Results deck (6 Feb 2026)
- Q2 FY26: Results deck (13 Nov 2025)
- Q1 FY26: Earnings call (19 Aug 2025)
- Q4 FY25: Results deck (28 May 2025)
- Other events: Strategy deck (14 Aug 2025)
Figures from the company's filings with NSE and BSE. Not investment advice.